Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Janux Therapeutics, Inc.NASDAQ: JANX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $469K fell 98.1% year over year, behind the -79.7% change in trailing-twelve-month cost of revenue. Sequentially, it fell 94.8% from the prior quarter. Over 3 fiscal years it compounded at +34.1% a year.

Context

  • Cost of revenue amounted to 20.3% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -98.1% toward the trailing-twelve-month pace of -79.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$469K-94.8% QoQ
Last fiscal yearDec 2025
$2.03M-1.5% YoY
LTMMar 2026
$9.91M-79.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.1%——
1 year-1.5%——
3-year CAGR+34.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
2.03M USD
Year-over-year change
-1.5%
4-year CAGR
-47.3%

Cost of Revenue vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -79.7% is the 5th highest of 8, against a peer median of -28.6%.
  • Cost of revenue amounts to 45.9% of revenue for JANX, versus a peer median of 15.7%.
JANX Competitors
Cost of Revenue for JANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$584.36M USD+63.0%+84.1%43.0%
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M USD-18.4%+80.2%30.1%
JANXJanux Therapeutics, Inc.LTM Mar 2026$9.91M USD-79.7%+34.1%45.9%
STROSutro Biopharma, Inc.LTM Mar 2026$1.28M USD-28.6%-4.0%1.3%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$854K USD-99.5%—762.5%
IMNMImmunome, Inc.LTM Sep 2026$753K USD-98.5%——
CMPXCompass Therapeutics, Inc.LTM Mar 2026$738K USD———
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$251K USD——0.7%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$79K USD+2.6%——
IMTXImmatics N.V.LTM Mar 2026€0 EUR-100.0%—0.0%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding JANX) —-28.6%+80.2%15.7%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.